0
0
CINCINNATI — In a discovery that could fundamentally reshape the understanding of Fanconi anemia (FA), researchers at Cincinnati Children’s Hospital Medical Center have identified a distinct metabolic “signature” in patients with the rare genetic disorder. The findings, published November 28, 2025, in Science Advances, reveal that cells in FA patients struggle to process glucose efficiently—a condition known as “metabolic inflexibility”—and instead default to burning fat, a process that may drive the disease’s notorious cancer risks.
Fanconi anemia is a life-limiting genetic condition best known for causing bone marrow failure and physical abnormalities. However, the most lethal threat for patients who survive childhood is an immensely elevated risk of aggressive cancers, particularly squamous cell carcinoma. For years, scientists have hunted for the biological triggers behind this susceptibility. The new study suggests the answer may lie in how these patients fuel their bodies.
Tracking the “Fuel” with Precision
To uncover this metabolic glitch, the research team employed a cutting-edge technique known as isotope tracing metabolomics. “Think of it as a GPS for nutrients,” explains the study’s lead author, Sara Vicente-Muñoz, PhD, a staff scientist at Cincinnati Children’s Translational Metabolomics Facility.
Participants in the study consumed a small amount of glucose containing “tagged” carbon atoms. This allowed researchers to track the sugar molecules in real-time as they moved through the patients’ metabolic pathways. In a healthy individual, the body would readily absorb this glucose and convert it into energy.
In FA patients, however, the results were striking. “The patterns revealed a profound metabolic inflexibility,” says Dr. Vicente-Muñoz. “Persons with FA appear to bypass normal glucose oxidation.”
Instead of using the available sugar, the patients’ bodies remained in a state of stress, leaving blood sugar levels high while simultaneously shifting gears to burn fat—a state known as ketosis—even when it wasn’t necessary.
A “Hybrid Car” Stuck in One Gear
Ideally, human metabolism acts like a hybrid car, seamlessly switching between burning sugar (glucose) and fat depending on fuel availability. The study indicates that in Fanconi anemia, this switch is jammed.
The implications of this “jammed switch” are far-reaching. The research team posits that this constant, inefficient fat-burning state could be contributing to the cellular stress and genomic instability that characterize FA.
“Understanding how FA rewires energy metabolism could lead to new strategies for improving health and reducing cancer,” notes Dr. Lindsey Romick-Rosendale, the study’s corresponding author and Director of the Translational Metabolomics Facility at Cincinnati Children’s.
Contextualizing the Findings
While Fanconi anemia is primarily defined by DNA repair defects, hints of metabolic dysfunction have long puzzled the medical community. Previous research has identified high rates of endocrine abnormalities, such as insulin resistance and abnormal lipid profiles, in this population.
Dr. Blanche P. Alter, a renowned expert at the National Cancer Institute (NCI) and a pioneer in FA epidemiology, has long established that the disorder affects nearly every organ system. This new data provides a mechanistic link, suggesting that these systemic issues—ranging from short stature to hormone imbalances—might share a common metabolic root.
“This work reflects years of effort and highlights the power of advanced metabolomics to illuminate disease mechanisms,” Dr. Romick-Rosendale adds.
Implications for Patients and Care
The discovery opens the door to potential dietary interventions. If FA patients cannot process glucose effectively, could a low-carbohydrate or ketogenic-style diet help align their intake with their metabolism?
The researchers are already planning a feasibility study to test whether a specialized low-carbohydrate diet can improve metabolic health in children with FA. However, experts urge extreme caution.
“Persons with FA are medically fragile and need continued expert guidance,” Dr. Romick-Rosendale emphasizes, warning families against making dietary changes without medical supervision. “Our next step is to test these theories safely in a clinical setting.”
A Step Toward Cancer Prevention?
The ultimate hope is that by correcting or managing this metabolic defect, clinicians might be able to lower the risk of cancer. If the metabolic stress contributes to DNA damage, relieving that stress could theoretically delay or prevent the onset of malignancies.
For a community that has long relied on bone marrow transplantation and watchful waiting, the prospect of a nutritional or metabolic therapy offers a new, proactive avenue for hope.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Primary Study: Vicente-Muñoz, S., et al. (2025). “Metabolic reprogramming in Fanconi anemia: Evidence of compromised glucose oxidation, enhanced ketogenesis, and metabolic inflexibility.” Science Advances. DOI: 10.1126/sciadv.ady6117.
-
Institutional Source: Cincinnati Children’s Hospital Medical Center. “Fanconi anemia patients show striking metabolic differences.” Research Horizons, Nov 29, 2025.
-
Contextual Research: Alter, B. P., et al. “Endocrine Abnormalities in Patients with Fanconi Anemia.” Journal of Clinical Endocrinology & Metabolism.
-
Additional Support: Research funded in part by the Fanconi Cancer Foundation.
For further understanding of the clinical landscape of this condition, the following video provides expert insights into the biology and management of Fanconi anemia.
New insights in Fanconi anemia
This video is relevant because it features Dr. Carlo Dufour, a leading hematologist, discussing the broader disease biology and treatment options for Fanconi anemia, providing essential context to the metabolic findings discussed in the article.
